News & Updates

Show Multimedia Only

First-line tislelizumab plus chemo shows benefit in nsq-NSCLC with high PD-L1 expression

15 May 2025 by

First-line treatment with tislelizumab plus chemotherapy showed better survival outcomes and response among patients with locally advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC), particularly those with high PD-L1 expression, compared with chemotherapy alone, according to a subgroup analysis of the phase III RATIONALE-304 trial presented at ELCC 2025.

First-line tislelizumab plus chemo shows benefit in nsq-NSCLC with high PD-L1 expression

15 May 2025

World’s first AI model for thyroid cancer diagnosis achieves high accuracy

15 May 2025 by

The world’s first artificial intelligence (AI) model for diagnosis of well-differentiated thyroid cancer, developed by researchers from the University of Hong Kong (HKU), has demonstrated high accuracy in staging and risk classification based on analysis of semi-structured free-text clinical notes.

World’s first AI model for thyroid cancer diagnosis achieves high accuracy

15 May 2025

AML treatment efficacy varies by status, age, cytogenetic risk

14 May 2025

Some of the important treatment options for patients with acute myeloid leukaemia (AML) include chemotherapy, targeted therapy, and immunotherapy, but the efficacy of these treatments may vary depending on AML status, age, and cytogenetic risk, according to a study.

AML treatment efficacy varies by status, age, cytogenetic risk

14 May 2025

Cardio-onco collab may enhance safety of nivolumab anticancer therapy

14 May 2025

The safety of nivolumab anticancer therapy may be improved through close collaboration between cardiology and oncology specialists, which can help detect cardiac complications early and manage these conditions effectively, suggests a study.

Cardio-onco collab may enhance safety of nivolumab anticancer therapy

14 May 2025

MIRASOL final analysis: MIRV remains superior to chemo for ovarian cancer

13 May 2025 by

In the final overall survival (OS) analysis of the phase III MIRASOL trial, the survival benefit previously reported with the antibody drug conjugate mirvetuximab soravtansine (MIRV) remains superior to investigator’s choice chemotherapy (ICC) for the treatment of folate receptor alpha-positive, platinum-resistant ovarian cancer (FRα+ PROC).

MIRASOL final analysis: MIRV remains superior to chemo for ovarian cancer

13 May 2025

Nerve-sparing technique preserves erectile function after RARP

13 May 2025 by

A nerve-sparing technique decreases erectile dysfunction in men undergoing robot-assisted radical prostatectomy (RARP) for prostate cancer in a phase III study.

Nerve-sparing technique preserves erectile function after RARP

13 May 2025

Sleeping well before undergoing surgery tied to smoother recovery

12 May 2025

Gynaecologic oncology patients with better sleep efficiency in the days before a surgical procedure are more likely to have fewer postoperative complications and require lower doses of opioid pain medication upon hospital discharge, according to a study.

Sleeping well before undergoing surgery tied to smoother recovery

12 May 2025

Exercise reduces odds of lower extremity lymphedema in endometrial cancer

10 May 2025

Regular physical activity appears to protect against lower extremity lymphedema in endometrial cancer survivors, as reported in a study.

Exercise reduces odds of lower extremity lymphedema in endometrial cancer

10 May 2025

Patient-reported outcome data support perioperative durvalumab for operable NSCLC

09 May 2025 by

In patients with resectable nonsmall cell lung cancer (NSCLC), adding perioperative durvalumab to neoadjuvant chemotherapy does not appear to have a detrimental impact on patient-reported health-related quality of life (QoL), functioning, or symptoms as compared with neoadjuvant chemotherapy alone, according to data from the phase III AEGEAN study.

Patient-reported outcome data support perioperative durvalumab for operable NSCLC

09 May 2025

MARIPOSA update: Amivantamab-lazertinib may extend survival beyond 4 years in EGFRm NSCLC

09 May 2025 by

In the protocol-specified final overall survival (OS) analysis of the phase III MARIPOSA trial, treatment with amivantamab plus lazertinib significantly reduced the risk of death in individuals with previously untreated EGFR-mutant (EGFRm) advanced non-small cell lung cancer (NSCLC).

MARIPOSA update: Amivantamab-lazertinib may extend survival beyond 4 years in EGFRm NSCLC

09 May 2025

News & Updates

Filter by Specialty:

Specialty:

First-line tislelizumab plus chemo shows benefit in nsq-NSCLC with high PD-L1 expression

First-line tislelizumab plus chemo shows benefit in nsq-NSCLC with high PD-L1 expression

World’s first AI model for thyroid cancer diagnosis achieves high accuracy

World’s first AI model for thyroid cancer diagnosis achieves high accuracy

AML treatment efficacy varies by status, age, cytogenetic risk

AML treatment efficacy varies by status, age, cytogenetic risk

Cardio-onco collab may enhance safety of nivolumab anticancer therapy

Cardio-onco collab may enhance safety of nivolumab anticancer therapy

MIRASOL final analysis: MIRV remains superior to chemo for ovarian cancer

MIRASOL final analysis: MIRV remains superior to chemo for ovarian cancer

Nerve-sparing technique preserves erectile function after RARP

Nerve-sparing technique preserves erectile function after RARP

Sleeping well before undergoing surgery tied to smoother recovery

Sleeping well before undergoing surgery tied to smoother recovery

Exercise reduces odds of lower extremity lymphedema in endometrial cancer

Exercise reduces odds of lower extremity lymphedema in endometrial cancer

Patient-reported outcome data support perioperative durvalumab for operable NSCLC

Patient-reported outcome data support perioperative durvalumab for operable NSCLC

MARIPOSA update: Amivantamab-lazertinib may extend survival beyond 4 years in EGFRm NSCLC

MARIPOSA update: Amivantamab-lazertinib may extend survival beyond 4 years in EGFRm NSCLC